1-(1-cyclooctylmethyl-4-piperidyl)-1,3-dihydro-2H-benzimidazol-2-one | 217461-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(1-cyclooctylmethyl-4-piperidyl)-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 1-(1-Cyclooctylmethyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one；3-[1-(cyclooctylmethyl)piperidin-4-yl]-1H-benzimidazol-2-one
• CAS: 217461-01-3
• 化学式: C₂₁H₃₁N₃O
• 分子量: 341.497
• InChiKey: JOVPNINDYCHWAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-cyclooctylmethyl-4-piperidyl)-1,3-dihydro-2H-benzimidazol-2-one 在 三氯氧磷 、 Ammonium hydroxide 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 96.0h， 以72.8%的产率得到2-chloro-1-(1-cyclooctylmethyl-4-piperidinyl)-1H-benzimidazole
  参考文献：
  名称：

  2-benzimidazolylamine compounds as ORL-1-receptor agonists

  摘要：

  该化合物的结构式为：或其药用可接受的盐，其中R1和R2独立选择自氢、卤素、羟基、(C1-C4)烷基、卤代(C1-C4)烷基等；R3和R4独立选择自氢、卤代(C1-C10)烷基、可选择取代的(C1-C6)烷基等，或者R3和R4与它们连接的氮原子一起形成一个可选择取代的完全饱和、部分饱和或完全不饱和的杂环环；R5为(C4-C11)环烷基等，具有ORL1受体激动剂活性，并且在哺乳动物体内可用作镇痛剂或类似物。

  公开号：

  US06340681B1
• 作为产物：
  描述：

  环辛烷甲醛 、 4-（2-酮酸-1-苯并咪唑）哌啶 在 sodium triacetylborohydride 作用下， 以 二氯甲烷 为溶剂， 以26.7 g的产率得到1-(1-cyclooctylmethyl-4-piperidyl)-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  2-benzimidazolylamine compounds as ORL-1-receptor agonists

  摘要：

  该化合物的结构式为：或其药用可接受的盐，其中R1和R2独立选择自氢、卤素、羟基、(C1-C4)烷基、卤代(C1-C4)烷基等；R3和R4独立选择自氢、卤代(C1-C10)烷基、可选择取代的(C1-C6)烷基等，或者R3和R4与它们连接的氮原子一起形成一个可选择取代的完全饱和、部分饱和或完全不饱和的杂环环；R5为(C4-C11)环烷基等，具有ORL1受体激动剂活性，并且在哺乳动物体内可用作镇痛剂或类似物。

  公开号：

  US06340681B1

文献信息

• 2-oxoimidazole derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US06258825B1

  公开（公告）日：2001-07-10

  The present invention relates to a compound represented by Formula [I] wherein represents an aromatic carbo- or heterocyclic ring which may have a substituent; Cy represents a mono-, bi- or tricyclic aliphatic carbocyclic group having 3 to 20 carbon atoms, which may have a substituent; represents a mono- or bicyclic aliphatic nitrogen-containing heterocyclic group having 3 to 14 carbon atoms, which may have a substituent; R1 represents a hydrogen atom, a lower alkenyl group, a lower alkynyl group, a cyclo(lower alkyl) group, an amino group, a lower alkylamino group, a di(lower alkyl)-amino group, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group or a di(lower alkyl)carbamoyl group, or a lower alkyl group which may have a substituent; and R2 represents a hydrogen atom or a lower alkyl group, a salt or ester thereof, a production process for the same, and an analgesic, a reliever against tolerance to a narcotic analgesic represented by morphine, a reliever against dependence on a narcotic analgesic represented by morphine, an analgesic enhancer, an antiobestic, a drug for ameliorating brain function, a remedy for schizophrenia, a remedy for Parkinsonism, a remedy for chorea, an antidepressant, a remedy for diabetes insipidus, a remedy for polyuria, or a remedy for hypotension, comprising an effective ingredient of the same.

  本发明涉及一种由式[I]表示的化合物 其中 代表可能具有取代基的芳香碳或杂环环；Cy代表具有3至20个碳原子的单、双或三环脂肪环烃基，可能具有取代基； 代表具有3至14个碳原子的单环或双环脂肪氮含杂环基，可能具有取代基；R1代表氢原子、较低的烯基基团、较低的炔基团、环状(较低烷基)基团、氨基、较低烷基氨基、二(较低烷基)-氨基、羟基、较低烷氧基、羧基、较低烷氧羰基、氨基甲酰基、较低烷基氨基甲酰基或二(较低烷基)氨基甲酰基，或可能具有取代基的较低烷基基团；R2代表氢原子或较低烷基基团，其盐或酯，以及其制备方法，以及一种镇痛剂，一种对抗吗啡所代表的麻醉镇痛剂的耐受性的缓解剂，一种对抗吗啡所代表的麻醉镇痛剂的依赖性的缓解剂，一种镇痛增强剂，一种抗肥胖剂，一种改善脑功能的药物，一种治疗精神分裂症的药物，一种治疗帕金森病的药物，一种治疗舞蹈病的药物，一种抗抑郁剂，一种治疗尿崩症的药物，一种治疗多尿症的药物，或一种治疗低血压的药物，包括其有效成分。
• Antipruritics
  申请人：——

  公开号：US20040116450A1

  公开（公告）日：2004-06-17

  The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scrtaching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

  本发明涉及一种抗瘙痒剂，其包含一种镇痛肽拮抗剂作为活性成分。该镇痛肽拮抗剂可用作与瘙痒有关的疾病的预防或治疗（例如，特应性皮炎和荨麻疹），由昆虫排泄物和分泌物引起的局部皮肤瘙痒，结节性瘙痒，肾透析，糖尿病，血液疾病，肝脏疾病，肾脏疾病，内分泌和代谢紊乱，内脏恶性肿瘤，甲状腺功能亢进，自身免疫疾病，多发性硬化症，神经系统疾病，精神神经症，过度使用泻药和药物引起的瘙痒，因为它具有出色的抓痒行为抑制作用，即抗瘙痒作用和抗瘙痒作用。
• 2-OXOIMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0990653A1

  公开（公告）日：2000-04-05

  The present invention relates to a compound represented by Formula [I] [wherein represents an aromatic carbo- or heterocyclic ring which may have a substituent; Cy represents a mono-, bi- or tricyclic aliphatic carbocyclic group having 3 to 20 carbon atoms, which may have a substituent; represents a mono- or bicyclic aliphatic nitrogen-containing heterocyclic group having 3 to 14 carbon atoms, which may have a substituent; R1 represents a hydrogen atom, a lower alkenyl group, a lower alkynyl group, a cyclo(lower alkyl) group, an amino group, a lower alkylamino group, a di(lower alkyl)amino group, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group or a di(lower alkyl)carbamoyl group, or a lower alkyl group which may have a substituent; and R 2 represents a hydrogen atom or a lower alkyl group], a salt or ester thereof, a production process for the same, and an analgesic, a reliever against tolerance to a narcotic analgesic represented by morphine, a reliever against dependence on a narcotic analgesic represented by morphine, an analgesic enhancer, an antiobestic, a drug for ameliorating brain function, a remedy for schizophrenia, a remedy for Parkinsonism, a remedy for chorea, an antidepressant, a remedy for diabetes insipidus, a remedy for polyuria, or a remedy for hypotension, comprising an effective ingredient of the same.

  本发明涉及一种由式[I]表示的化合物 其中 代表芳香族碳环或杂环，可以有取代基； Cy 代表具有 3 至 20 个碳原子的单环、双环或三环脂族碳环基团，可以有取代基； 代表具有 3 至 14 个碳原子的单环或双环脂族含氮杂环基团，该基团可具有取代基；R1 代表氢原子、低级烯基、低级炔基、环(低级烷基)基团、氨基、低级烷基氨基、二(低级烷基)氨基、羟基、低级烷氧基、羧基、低级烷氧羰基、氨基甲酰基、低级烷基氨基甲酰基或二(低级烷基)氨基甲酰基，或可带有取代基的低级烷基；以及 R 2 代表氢原子或低级烷基]，其盐或酯，其生产工艺，以及一种镇痛剂、一种防止对以吗啡为代表的麻醉性镇痛剂产生耐受性的缓解剂、一种防止对以吗啡为代表的麻醉性镇痛剂产生依赖性的缓解剂、一种镇痛增强剂、一种抗抑郁剂、一种改善脑功能的药物、一种治疗精神分裂症的药物、一种治疗帕金森病的药物、一种治疗舞蹈症的药物、一种抗抑郁剂、一种治疗糖尿病的药物、一种治疗多尿症的药物或一种治疗低血压的药物，其中包括一种有效成分。
• ANTIPRURITICS
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1371376A1

  公开（公告）日：2003-12-17

  The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scrtaching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

  本发明涉及一种止痒剂，其活性成分包括一种神经痛素拮抗剂。痛觉素拮抗剂可用于预防或治疗与瘙痒有关的疾病（例如特应性皮炎和荨麻疹）、昆虫排泄和分泌物引起的局部皮肤瘙痒症、结节性瘙痒症、肾透析、糖尿病、血液病、肝病、肾病、增生和代谢紊乱、内脏恶性肿瘤、甲状腺机能亢进症、自身免疫性疾病、多发性硬化症、神经系统疾病、精神神经症、过敏性结膜炎、春季白内障、特应性角结膜炎，或过量使用泻药和药物引起的瘙痒，因为它具有出色的抑制瘙痒行为的效果，即止痒效果和止痒效果。
• US6258825B1
  申请人：——

  公开号：US6258825B1

  公开（公告）日：2001-07-10